Inclusion Criteria:  age 18 to 70 years, regardless of gender. histologically confirmed nasopharyngeal carcinoma. T1-3N0-2 (stageII-III) with metastatic lymph nodes ≤ 4 cm in maximum diameter and no extra nodal extension（ENE）. KPS score ≥ 70. completed pre-treatment CT/MRI imaging data (including functional MRI sequences) with measurable tumor lesions. the first course of therapy. expected survival longer than 6 months. laboratory criteria: Hb >120g/L, white blood cells ≥4x109 /L, ≥100x109 /L, liver and kidney function indicators within the upper limit of normal values 1.25 more range; no hearing impairment. can understand the study and have signed the informed consent form. have the conditions for follow-up.  Exclusion Criteria:  maximum diameter of metastatic lymph nodes > 4 cm. gross melted Cervical lymph nodes or extra nodal extension. jumping metastases of cervical lymph nodes. T4 or N3 stage. has other malignancies (other than stage I non-melanotic skin cancer or carcinoma in situ of the cervix). has received other tumor-related treatment. pregnant or breastfeeding, and women of childbearing age. undergoing trials of other drugs. with severe comorbidities, including myocardial infarction, severe arrhythmias, severe cerebrovascular disease, ulcer disease, psychiatric disorders and uncontrollable diabetes mellitus. do not have the condition of regular follow-up.